Future Oncol
-
Publication Venue For
- KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer. 2023
- Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia. 2022
- Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide? 2022
- Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.. 18:3609-3621. 2022
- Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.. 18:3701-3711. 2022
- Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.. 18:3011-3020. 2022
- Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.. 18:35-45. 2022
- Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.. 17:4431-4446. 2021
- Navigating the high costs of cancer care: opportunities for patient engagement.. 17:3729-3742. 2021
- Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.. 17:2923-2939. 2021
- Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.. 17:3137-3150. 2021
- Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.. 17:403-409. 2021
- Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma.. 16:39-47. 2020
- Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.. 15:2413-2422. 2019
- The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. 15:1683-1695. 2019
- Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.. 15:1067-1084. 2019
- Gene expression profiling in melanoma: past results and future potential.. 15:791-800. 2019
- The National Physicians Cooperative: transforming fertility management in the cancer setting and beyond.. 14:3059-3072. 2018
- Bevacizumab biosimilars: scientific justification for extrapolation of indications.. 14:2507-2520. 2018
- Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.. 13:1385-1393. 2017
- Cabozantinib in genitourinary malignancies.. 13:755-765. 2017
- Integration of multiparametric MRI into active surveillance of prostate cancer.. 12:2513-2529. 2016
- Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.. 12:1359-1367. 2016
- Corrigendum.. 11:544. 2015
- The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature.. 10:2189-2199. 2014
- Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.. 9:977-990. 2013
- Targeting the epigenome in ovarian cancer.. 8:151-164. 2012
- The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.. 7:519-541. 2011
- A promising cancer vaccine.. 7:331-334. 2011
- Aptamer applications for targeted cancer therapy.. 6:1117-1126. 2010
- Immunohistochemistry in the diagnosis of cutaneous neoplasms.. 6:93-109. 2010
- Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation.. 6:127-148. 2010
- Nanomolecular targeting of dendritic cells for ovarian cancer therapy.. 5:1189-1192. 2009
- Combating immunosuppression in glioma.. 4:433-442. 2008
- Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?. 4:241-255. 2008
- Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction.. 3:649-654. 2007